Dr. Michael D. Green
Claim this profileUniversity of Michigan Comprehensive Cancer Center EDDOP
Affiliated Hospitals
University Of Michigan Comprehensive Cancer Center EDDOP
Veterans Affairs Ann Arbor Healthcare System
Clinical Trials Michael D. Green is currently running
Durvalumab + Olaparib with Radiation
for Pancreatic Cancer
This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable). Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. The combination of targeted therapy with olaparib, immunotherapy with durvalumab and radiation therapy may stimulate an anti-tumor immune response and promote tumor control in locally advanced unresectable pancreatic cancer.
Recruiting
1 award
Phase 1
25 criteria
SBRT + Pembrolizumab
for Lung Cancer
Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
Recruiting
2 awards
Phase 1
9 criteria
More about Michael D. Green
Clinical Trial Related
2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Michael D. Green has experience with
- Durvalumab
- Olaparib
- Radiation Therapy
- Liver SBRT
- Pembrolizumab
- Ipilimumab
Breakdown of trials Michael D. Green has run
Liver Metastases
Pancreatic Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael D. Green specialize in?
Michael D. Green focuses on Liver Metastases and Pancreatic Cancer. In particular, much of their work with Liver Metastases has involved Stage IV patients, or patients who are undergoing treatment.
Is Michael D. Green currently recruiting for clinical trials?
Yes, Michael D. Green is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Michael D. Green has studied deeply?
Yes, Michael D. Green has studied treatments such as Durvalumab, Olaparib, Radiation Therapy.
What is the best way to schedule an appointment with Michael D. Green?
Apply for one of the trials that Michael D. Green is conducting.
What is the office address of Michael D. Green?
The office of Michael D. Green is located at: University of Michigan Comprehensive Cancer Center EDDOP, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Comprehensive Cancer Center EDDOP.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.